Continual low-dose metronomic chemotherapy as potentially preferable to aggressive strategies

Visit http://www.ecancer.org for more. Prof Shaked (Israel Institute of Technology, Haifa, Israel) talks to ecancertv at the Metronomic Chemotherapy Meeting in Milan about the benefits of a metronomic chemotherapy regimen as a less aggressive treatment than high dose chemotherapy and a more effective maintenance drug, preventing relapse and decreasing metastic burden.